KKR & Flerie Form New Platform To Drive Specialized Pharma Services, Invest In Munich-Based Coriolis Pharma

KKR & Co Inc KKR, in collaboration with Flerie, disclosed the formation of a new global pharma services platform, Frontier Biosolutions.

Frontier will invest in a portfolio of companies focused on specialized pharmaceutical services to advanced therapeutics customers.

The platform plans to invest in differentiated scientific capabilities and proprietary technology platforms that manage critical bottlenecks in developing and manufacturing advanced therapeutics.

The companies brought in industry veteran and co-investor Thomas Eldered as Frontier's Executive Chairman.

As an initial investment, KKR and Flerie have invested in Munich-based Coriolis Pharma, which deals in formulation research and development, analytical services, and non-GMP manufacturing of inventive high-value biologics and cell and gene therapy products.

The investment is expected to drive Coriolis' expansion strategy in the fast-growing cell and gene therapy segment and boost its range of global services.

"We are thrilled to partner with Flerie and Thomas Eldered, the experienced Board of Directors, and the team at Coriolis Pharma at a time of growing demand for specialized services to support the development of advanced therapeutics. This platform and the investment in Coriolis Pharma are another example of our Health Care Strategic Growth platform strategy to partner with proven operators in an area we have been following for some time," said Kugan Sathiyanandarajah, Managing Director and Head of KKR's Health Care Strategic Growth business in Europe. 

KKR's investment in Coriolis Pharma underlines its strong presence in the DACH region, where it has invested over €15 billion of long-term equity capital across more than 30 companies since 1999. 

Also Read: KKR Sells $560M In Industrial Assets, Keeps Focus On Logistics In Growth Markets

Price Action: KKR shares closed lower by 1.71% at $60.25 on Friday.